AIM: Pharmacogenetics of @entity1499 ( @entity1500 ) contributes to interindividual differences in @entity137 . We aimed to evaluate the impact of SNPs within the @entity1500 pathway genes on @entity1500 -induced @entity137 and @entity1500 plasma levels at 48 h following treatment in Asian adults with @entity981 or @entity1893 . @entity1 _ METHODS: @entity1 (n = 71) were genotyped for @entity9769 @entity9770 , @entity9769 @entity24038 , @entity7177 @entity47607 , @entity10430 @entity47423 and @entity1262 @entity7658 using the Sequenom MassARRAY(  ) platform. Plasma @entity1500 concentrations at 48 h were measured by fluorescence polarization immunoassay. RESULTS: Forty-eight @entity1 had @entity137 , 51 had hepatic @entity137 and 36 had @entity33 . @entity1 homozygous for @entity9769 677TT were associated with increased risk of both hematopoietic (odds ratio [OR]: 9.03; 95% CI: 2.28-36.16; p = 0.002) and hepatic (OR: 3.92; 95% CI: 1.01-15.11; p = 0.036) @entity137 . @entity99 was associated with @entity7177 @entity47607 (OR: 5.27, 95% CI: 1.21-22.72; p = 0.032) and @entity1262 @entity7658 (OR: 8.62; 95% CI: 1.96-37.57; p = 0.004). However, polymorphisms in @entity9769 @entity24038 and @entity10430 @entity47423 were not associated with any of the @entity137 , and @entity33 was not associated with any polymorphisms of the @entity1500 pathway genes. @entity1 with @entity9769 @entity9770 and @entity1262 @entity7658 polymorphisms appear to have significantly higher @entity1500 plasma concentrations (p < 0.05). CONCLUSION: Our results in Asian adults provides evidence for the contribution pharmacogenetics to the @entity137 of high-dose @entity1500 and plasma @entity1500 concentrations at 48 h following treatment in @entity1 with @entity981 or @entity1893 . These results will contribute towards the effort of @entity1500 therapy individualization. Original submitted 24 April 2014; Revision submitted 6 June 2014.

Effect of polymorphisms within @entity1499 pathway genes on @entity1499 XXXX and plasma levels in adults with hematological malignancies.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity1262 :: ('5243', 'Gene') :: ['ABCB1'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities', 'hematopoietic toxicity', 'toxicity'] @entity981 :: ('MESH:D054198', 'Disease') :: ['acute lymphoblastic leukemia'] @entity9769 :: ('4524', 'Gene') :: ['MTHFR'] @entity9770 :: ('c|SUB|C|677|T', 'DNAMutation') :: ['C677T'] @entity47423 :: ('c|SUB|C|421|A', 'DNAMutation') :: ['C421A'] @entity10430 :: ('9429', 'Gene') :: ['ABCG2'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity24038 :: ('c|SUB|A|1298|C', 'DNAMutation') :: ['A1298C'] @entity7177 :: ('6573', 'Gene') :: ['SLC19A1'] @entity1500 :: ('CHEBI:44185', 'Chemical') :: ['MTX'] @entity47607 :: ('c|SUB|G|80|A', 'DNAMutation') :: ['G80A'] @entity1893 :: ('MESH:D008228', 'Disease') :: ['non-Hodgkin lymphoma'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity99 :: ('MESH:D056486', 'Disease') :: ['Hepatic toxicity'] @entity7658 :: ('c|SUB|C|3435|T', 'DNAMutation') :: ['C3435T']
@entity137 :: (MESH:D064420,Disease) :: ['toxicity']
